HUTCHMED (China) Ltd (HCM)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-10-01 Phase1 Readout
2026-12-01 Phase1 Readout

Active Clinical Trials (12)

NCT #TitlePhaseStatusEnrollment
NCT07409428 A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL PHASE3 Recruiting 240
NCT04353375 HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma PHASE3 Recruiting 235
NCT05522231 Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) PHASE3 Active Not Recruiting 265
NCT06387069 A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia PHASE3 Recruiting 316
NCT05535933 HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia PHASE3 Active Not Recruiting 111
NCT06361888 A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and ... PHASE3 Recruiting 502
NCT06584032 Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer PHASE3 Recruiting 412
NCT07228247 A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors PHASE2 Recruiting 147
NCT07396584 HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor PHASE2 Recruiting 186
NCT06601504 Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL PHASE2 Active Not Recruiting 61
NCT06387082 A Clinical Study of HMPL-506 in Patients With Hematological Malignancies PHASE1 Recruiting 132
NCT07025018 Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations PHASE1 Recruiting 52

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis